|Bid||18.50 x 1100|
|Ask||18.53 x 1000|
|Day's Range||18.33 - 18.89|
|52 Week Range||12.81 - 37.66|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 3, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.57|
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today presented a post-hoc analysis of Phase 3 data from different patient populations included in the ACTIVE trial, and results from preclinical studies of abaloparatide and its effect on the development and growth of osteoclasts and on bone resorption during an oral session at ENDO 2019, the Endocrine Society’s Annual Meeting and Expo in New Orleans, LA. The first oral presentation titled “The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis,” showed that in a subpopulation of postmenopausal women from the ACTIVE study who also had osteoarthritis (OA), abaloparatide was associated with significant reduction in new vertebral fractures as well as significant improvements in bone mineral density (BMD), versus placebo.
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will present data on TYMLOS® (abaloparatide) injection at ENDO 2019, the Endocrine Society’s Annual Meeting and Expo in New Orleans, LA. During an oral session, Radius Health will present two abstracts on abaloparatide injection: a post-hoc analysis in a subset of women from the Phase 3 ACTIVE trial who have both postmenopausal osteoporosis (PMO) and osteoarthritis, and data from preclinical studies that provide mechanistic explanations for the net bone gain observed in ACTIVE in abaloparatide-treated patients.
Radius Health Inc NASDAQ NMS:RDUSView full report here! Summary * Bearish sentiment is moderate Bearish sentimentShort interest | PositiveShort interest is moderate for RDUS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold RDUS had net inflows of $1.54 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
WALTHAM, Mass., March 11, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at.
While not a mind-blowing move, it is good to see that the Radius Health, Inc. (NASDAQ:RDUS) share price has gained 15% in the last three months. But in truth theRead More...
Radius Health (RDUS) posts narrower-than-expected Q4 loss as Tymlos sales gain traction and capture additional market share.
WALTHAM, Mass., March 01, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse.
TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018 and totaling $99.2 million for full-year 2018, exceeding the Company’s.
WALTHAM, Mass., Feb. 19, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at.
WALTHAM, Mass., Feb. 14, 2019 -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2018 financial results on Thursday, February.
Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Br, Feb. 06, 2019 -- In new independent research reports released early this.
Radius Health, Inc. (“Radius” or the “Company”) (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced the appointment of Dr. Jessica Hopfield to its Board of Directors. Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice and is currently the Chair of the Board of Trustees of the Joslin Diabetes Center.
If you're interested in Radius Health, Inc. (NASDAQ:RDUS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Radius Health, Inc. (RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million. 2019 will be a pivotal year for us as we move closer to our goal of U.S. anabolic market leadership and expect to advance our late-stage clinical pipeline of two innovative Phase 3 products, elacestrant and abaloparatide-patch, both with blockbuster potential,” said Jesper Hoeiland, President and Chief Executive Officer of Radius. Elacestrant’s Phase 3 EMERALD study was initiated in December 2018.
WALTHAM, Mass., Jan. 02, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update.
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The one and a half month time period since the end of the […]
LogicBio Therapeutics, Inc. (LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment biopharmaceutical industry leaders Richard Moscicki, M.D. and Michael Wyzga to its Board of Directors. Both have extensive knowledge of rare disease drug development and bring rich insight in the areas of clinical research, regulatory affairs and corporate governance to the board. “Richard and Michael bring tremendous value and expertise to our board, and we’re delighted to be able to draw on their insights as we move toward the clinic in our first indication, the rare genetic disorder methylmalonic acidemia,” said Frederic Chereau, LogicBio’s President and Chief Executive Officer.